Fibroblast growth factor 21 enhances cholesterol efflux in THP-1 macrophage-derived foam cells

Molecular Medicine Reports

Volumn 11, Issue 1, 2015, Pages 503-508

  Shang, Wei ^a   Yu, Xuejing ^a   Wang, Honglian ^b   Chen, Tielin ^b   Fang, Ying ^b   Yang, Xianggui ^a   Zhou, Puhui ^a   Nie, Fang ^a   Zhou, Qin ^a,b   Zhou, Jianzhong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Atherosclerosis; ATP binding casette A1; ATP binding casette G1; Cholesterol effl ux; Fibroblast growth factor 21; Liver X receptor

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; CHOLESTEROL; FIBROBLAST GROWTH FACTOR 21; HIGH DENSITY LIPOPROTEIN; LIVER X RECEPTOR ALPHA; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN; RECOMBINANT FIBROBLAST GROWTH FACTOR; SMALL INTERFERING RNA; ABC TRANSPORTER; ABCG1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR;

ARTICLE; CELL STIMULATION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FOAM CELL; GENE SILENCING; HUMAN; HUMAN CELL; LIQUID SCINTILLATION COUNTING; MACROPHAGE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL LINE; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; MOUSE;

ANIMALS; APOLIPOPROTEIN A-I; ATP BINDING CASSETTE TRANSPORTER 1; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CHOLESTEROL; FEMALE; FIBROBLAST GROWTH FACTORS; FOAM CELLS; HUMANS; MICE; ORPHAN NUCLEAR RECEPTORS; UP-REGULATION;

EID: 84916234343     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2731     Document Type: Article

References (28)

1. Lusis AJ: Atherosclerosis. Nature 407: 233-241, 2000.
2. Maxfeld FR and Tabas I: Role of cholesterol and lipid organization in disease. Nature 438: 612-621, 2005.
3. Rader DJ, Alexander ET, Weibel GL, Billheimer J and Rothblat GH: The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 50 (Suppl): S189-194, 2009.
4. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT and Schaefer EJ: HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57: 392-410, 2011.
5. Lewis GF and Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96: 1221-1232, 2005.
6. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, et al: Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125: 1905-1919, 2012.
7. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, et al: Cholesterol effux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127-135, 2011.
8. Yu XH, Fu YC, Zhang DW, Yin K and Tang CK: Foam cells in atherosclerosis. Clin Chim Acta 424: 245-252, 2013.
9. Hu YW, Wang Q, Ma X, Li XX, Liu XH, Xiao J, Liao DF, Xiang J and Tang CK: TGF-beta1 up-regulates expression of ABCA1, ABCG1 and SR-BI through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. J Atheroscler Thromb 17: 493-502, 2010.
10. Ni ZL, Zhao SP and Wu Z: ABCG1-a potential therapeutic target for atherosclerosis. Med Hypotheses 69: 214-217, 2007.
11. Zhao C and Dahlman-Wright K: Liver X receptor in cholesterol metabolism. J Endocrinol 204: 233-240, 2010.
12. Tang SL, Chen WJ, Yin K, Zhao GJ, Mo ZC, Lv YC, Ouyang XP, Yu XH, Kuang HJ, Jiang ZS, et al: PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXRα through the IGF-I-mediated signaling pathway. Atherosclerosis 222: 344-354, 2012.
13. Woo YC, Xu A, Wang Y and Lam KS: Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 78: 489-496, 2013.
14. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, et al: FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635, 2005.
15. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H and Gromada J: Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55: 2470-2478, 2006.
16. Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, Patel J, Ge H, Weiszmann J, Lu SC, Graham M, et al: Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 297: E1105-E1114, 2009.
17. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, Inoue K, Fushiki T and Itoh N: Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150: 4625-4633, 2009.
18. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ and Kliewer SA: Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 8: 77-83, 2008.
19. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE and Kharitonenkov A: Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149: 6018-6027, 2008.
20. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB and Etgen GJ: The metabolic state of diabetic monkeys is regulated by fbroblast growth factor-21. Endocrinology 148: 774-781, 2007.
21. Ma AZ, Zhang Q and Song ZY: TNFa alter cholesterol metabolism in human macrophages via PKC-θ-dependent pathway. BMC Biochem 14: 20, 2013.
22. Chen SG, Xiao J, Liu XH, Liu MM, Mo ZC, Yin K, Zhao GJ, Jiang J, Cui LB, Tan CZ, et al: Ibrolipim increases ABCA1/G1 expression by the LXRα signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin 31: 1343-1349, 2010.
23. Yan JQ, Tan CZ, Wu JH, Zhang DC, Chen JL, Zeng BY, Jiang YP, Nie J, Liu W, Liu Q, et al: Neopterin negatively regulates expression of ABCA1 and ABCG1 by the LXRα signaling pathway in THP-1 macrophage-derived foam cells. Mol Cell Biochem 379: 123-131, 2013.
24. Jessup W, Gelissen IC, Gaus K and Kritharides L: Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macro-phages. Curr Opin Lipidol 17: 247-257, 2006.
25. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D and Patsch W: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104: 1108-1113, 2001.
26. Gordon DJ and Rifkind BM: High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321: 1311-1316, 1989.
27. Otocka-Kmiecik A, Mikhailidis D P, Nicholls SJ, Davidson M, Rysz J and Banach M: Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 51: 314-324, 2012.
28. Meurs I, Van Eck M and Van Berkel TJ: High-density lipo-protein: key molecule in cholesterol effux and the prevention of atherosclerosis. Curr Pharm Des 16: 1445-1467, 2010.